World Cancer Day
Today marks the 20th #WorldCancerDay, a global initiative led by the Union for International Cancer Control (UICC). By raising worldwide awareness with campaigns like #IAmAndIWill, improving education, and organizing personal, collective, and government action, the UICC is reimagining a world where cancer is preventable and access to life-saving treatments is equal for everyone everywhere.
While there is much work to be done to manifest the UICC vision, Hapatune wishes to recognize some of the most recent oncology drug approvals by FDA:
- Dec 20, 2019: Daiichi Sankyo was granted approval of Enhertu (fam-trastuzumab deruxtecan-nxki), a novel antibody-drug conjugate for the treatment of unresectable or metastatic cancer HER2-positive breast cancer.
- Dec 18, 2019: Astellas Pharma US was granted accelerated approval of Padcev (enfortumab vedotin-ejfv), a novel antibody drug conjugate to treat refractory bladder cancer.
- Nov 14, 2019: BeiGene was granted accelerated approval for their orphan drug Brukinsa (zanubrutinib), a BTK inhibitor, to treat certain patients with mantle cell lymphoma, a form of blood cancer.
Together, let’s work to create a world without cancer!
As your biopharma customers develop these ever-improving cancer medicines, you want to be there to support them with your products and services. If you have questions on how to adapt your business to engage them, raise your brand awareness, or increase your lead generation, fill out the form below and we’ll be in touch very soon.
Stay connected with Hapatune and receive bioprocess market trends, marketing insights, industry tidbits and Hapatune happenings.